Sowell Financial Services LLC Purchases 1,057 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Sowell Financial Services LLC lifted its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 72.6% in the 1st quarter, Holdings Channel.com reports. The fund owned 2,512 shares of the biotechnology company’s stock after buying an additional 1,057 shares during the quarter. Sowell Financial Services LLC’s holdings in Aurinia Pharmaceuticals were worth $31,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in AUPH. Parallel Advisors LLC increased its position in shares of Aurinia Pharmaceuticals by 5,828.6% during the fourth quarter. Parallel Advisors LLC now owns 4,150 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 4,080 shares in the last quarter. CIBC Asset Management Inc increased its position in shares of Aurinia Pharmaceuticals by 10.3% during the fourth quarter. CIBC Asset Management Inc now owns 74,208 shares of the biotechnology company’s stock valued at $1,021,000 after acquiring an additional 6,914 shares in the last quarter. Alliancebernstein L.P. bought a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter valued at approximately $316,000. Thompson Siegel & Walmsley LLC bought a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter valued at approximately $207,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter valued at approximately $814,000. 40.79% of the stock is owned by institutional investors.

Shares of Aurinia Pharmaceuticals stock opened at $12.66 on Friday. The stock’s fifty day simple moving average is $12.62. The stock has a market cap of $1.62 billion, a PE ratio of -12.79 and a beta of 0.58. Aurinia Pharmaceuticals Inc. has a 1-year low of $9.72 and a 1-year high of $20.50.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Wednesday, May 5th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.05). The business had revenue of $0.91 million for the quarter, compared to analysts’ expectations of $2.30 million. Aurinia Pharmaceuticals had a negative return on equity of 34.48% and a negative net margin of 239.29%. Equities research analysts expect that Aurinia Pharmaceuticals Inc. will post -1.19 earnings per share for the current fiscal year.

In other news, Director Jill Leversage bought 2,500 shares of the stock in a transaction that occurred on Tuesday, May 11th. The shares were bought at an average price of $10.96 per share, for a total transaction of $27,400.00. Following the purchase, the director now owns 3,700 shares in the company, valued at $40,552. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Peter Greenleaf bought 5,125 shares of the stock in a transaction that occurred on Tuesday, May 11th. The shares were purchased at an average price of $10.71 per share, for a total transaction of $54,888.75. Following the purchase, the chief executive officer now owns 10,461 shares in the company, valued at approximately $112,037.31. The disclosure for this purchase can be found here. Insiders have bought a total of 18,525 shares of company stock worth $191,722 in the last quarter. Corporate insiders own 3.10% of the company’s stock.

AUPH has been the subject of several analyst reports. Royal Bank of Canada reduced their price target on shares of Aurinia Pharmaceuticals from $26.00 to $23.00 and set an “outperform” rating for the company in a research report on Friday, May 7th. Bloom Burton raised shares of Aurinia Pharmaceuticals from an “accumulate” rating to a “buy” rating in a research report on Friday, May 7th. SVB Leerink reaffirmed a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Sunday, April 11th. Oppenheimer reaffirmed a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Friday, May 7th. Finally, Zacks Investment Research downgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, April 27th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $26.29.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

Featured Story: What is the Hang Seng index?  

Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP).

Institutional Ownership by Quarter for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.